Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.

IF 4.2 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-09-27 DOI:10.1093/oncolo/oyaf318

Guangpeng Chen, Jianbo Zhu, Chunli Jian, Xu Chen, Kai Niu, Qiao Yang, Shu Tang, Si Qin, Yongdong Feng, Lijiao Xie, Wenlei Zhuo, Jianguo Sun

{"title":"Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.","authors":"Guangpeng Chen, Jianbo Zhu, Chunli Jian, Xu Chen, Kai Niu, Qiao Yang, Shu Tang, Si Qin, Yongdong Feng, Lijiao Xie, Wenlei Zhuo, Jianguo Sun","doi":"10.1093/oncolo/oyaf318","DOIUrl":null,"url":null,"abstract":"Background: Radiation pneumonitis (RP) is the common adverse event related to thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). The treatment of RP needs to be improved.Methods: NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into two groups: Rh-endostatin group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.Results: A total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15.0% vs. 45%, P = 0.038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs. 1.47 months, P = 0.048). The RP mortality rate was 5.0% and 35.0% in the Rh-endostatin group and control group, respectivly (P = 0.044). The incidence of pulmonary fibrosis was numerically lower in Rh-endostatin group (25.0% vs.45.0%, P = 0.185). The circulating lymphocyte levels in Rh-endostatin group significantly increased after treatment, when compared to the control group. The median progression-free survival was 7.8 months and 6.0 months respectively (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.40-2.23, P = 0.910). The median overall survival was 16.0 months and 7.7 months in two groups respectively (HR 0.56, 95%CI 0.27-1.16, P = 0.119). There was no significant difference between the two groups in adverse events.Conclusion: This prospective randomized study provides evidence that the combination of Rh-endostatin and glucocorticoids can reduce RP relapse rates and promote remission without increasing adverse events in advanced NSCLC patients.Discussion: This Discussion can take one of two forms: 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph; or 450 words with a single salient graphic. This discussion is part of the Abstract and as such needs to be distinct from the extended Discussion at the end of the paper. Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf318","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Radiation pneumonitis (RP) is the common adverse event related to thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). The treatment of RP needs to be improved.

Methods: NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into two groups: Rh-endostatin group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.

Results: A total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15.0% vs. 45%, P = 0.038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs. 1.47 months, P = 0.048). The RP mortality rate was 5.0% and 35.0% in the Rh-endostatin group and control group, respectivly (P = 0.044). The incidence of pulmonary fibrosis was numerically lower in Rh-endostatin group (25.0% vs.45.0%, P = 0.185). The circulating lymphocyte levels in Rh-endostatin group significantly increased after treatment, when compared to the control group. The median progression-free survival was 7.8 months and 6.0 months respectively (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.40-2.23, P = 0.910). The median overall survival was 16.0 months and 7.7 months in two groups respectively (HR 0.56, 95%CI 0.27-1.16, P = 0.119). There was no significant difference between the two groups in adverse events.

Conclusion: This prospective randomized study provides evidence that the combination of Rh-endostatin and glucocorticoids can reduce RP relapse rates and promote remission without increasing adverse events in advanced NSCLC patients.

Discussion: This Discussion can take one of two forms: 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph; or 450 words with a single salient graphic. This discussion is part of the Abstract and as such needs to be distinct from the extended Discussion at the end of the paper. Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.

查看原文本刊更多论文

rh -内皮抑素治疗非小细胞肺癌放射性肺炎的疗效和安全性。

背景：放射性肺炎（RP）是与非小细胞肺癌（NSCLC）患者胸部放疗相关的常见不良事件。RP的治疗方法有待改进。方法：纳入2级及以上RP的NSCLC患者，随机分为rh -内皮抑素组（rh -内皮抑素+糖皮质激素）和对照组（仅糖皮质激素）两组。主要终点为RP复发率。结果：共纳入40例患者。rh -内皮抑素组RP复发率明显低于对照组（15.0% vs. 45%, P = 0.038）。虽然两组RP缓解率相似，但联合治疗显著缩短了RP治疗至RP缓解的间隔时间（0.92个月vs 1.47个月，P = 0.048）。rh -内皮抑素组和对照组RP死亡率分别为5.0%和35.0% （P = 0.044）。rh -内皮抑素组肺纤维化发生率较低（25.0% vs 45.0%, P = 0.185）。与对照组相比，rh -内皮抑素组治疗后循环淋巴细胞水平明显升高。中位无进展生存期分别为7.8个月和6.0个月（风险比[HR] 0.95, 95%可信区间[CI] 0.40-2.23, P = 0.910）。两组患者的中位总生存期分别为16.0个月和7.7个月（HR 0.56, 95%CI 0.27 ~ 1.16, P = 0.119）。两组不良事件发生率无显著差异。结论：这项前瞻性随机研究提供了证据，证明rh -内皮抑制素和糖皮质激素联合使用可以降低晚期NSCLC患者RP复发率并促进缓解，而不会增加不良事件。讨论：这种讨论可以采用以下两种形式之一：350个单词和两个突出的图形，如表格、图式、瀑布图、图像或图表；或者用450个单词加上一个突出的图表。这个讨论是摘要的一部分，因此需要与论文末尾的扩展讨论区分开来。参考文献的引用应在CTR最后的扩展讨论中进行；只有在绝对必要的情况下，才能在作者摘要中引用参考文献（最多5篇）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.